234 related articles for article (PubMed ID: 33772213)
21. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Miller JJ; Gonzalez Castro LN; McBrayer S; Weller M; Cloughesy T; Portnow J; Andronesi O; Barnholtz-Sloan JS; Baumert BG; Berger MS; Bi WL; Bindra R; Cahill DP; Chang SM; Costello JF; Horbinski C; Huang RY; Jenkins RB; Ligon KL; Mellinghoff IK; Nabors LB; Platten M; Reardon DA; Shi DD; Schiff D; Wick W; Yan H; von Deimling A; van den Bent M; Kaelin WG; Wen PY
Neuro Oncol; 2023 Jan; 25(1):4-25. PubMed ID: 36239925
[TBL] [Abstract][Full Text] [Related]
22. DNA damage in IDH-mutant gliomas: mechanisms and clinical implications.
Shi DD; Anand S; Abdullah KG; McBrayer SK
J Neurooncol; 2023 May; 162(3):515-523. PubMed ID: 36352183
[TBL] [Abstract][Full Text] [Related]
23. ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma.
Babikir H; Wang L; Shamardani K; Catalan F; Sudhir S; Aghi MK; Raleigh DR; Phillips JJ; Diaz AA
Genome Biol; 2021 Nov; 22(1):311. PubMed ID: 34763709
[TBL] [Abstract][Full Text] [Related]
24. De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma.
Shi DD; Savani MR; Levitt MM; Wang AC; Endress JE; Bird CE; Buehler J; Stopka SA; Regan MS; Lin YF; Puliyappadamba VT; Gao W; Khanal J; Evans L; Lee JH; Guo L; Xiao Y; Xu M; Huang B; Jennings RB; Bonal DM; Martin-Sandoval MS; Dang T; Gattie LC; Cameron AB; Lee S; Asara JM; Kornblum HI; Mak TW; Looper RE; Nguyen QD; Signoretti S; Gradl S; Sutter A; Jeffers M; Janzer A; Lehrman MA; Zacharias LG; Mathews TP; Losman JA; Richardson TE; Cahill DP; DeBerardinis RJ; Ligon KL; Xu L; Ly P; Agar NYR; Abdullah KG; Harris IS; Kaelin WG; McBrayer SK
Cancer Cell; 2022 Sep; 40(9):939-956.e16. PubMed ID: 35985343
[TBL] [Abstract][Full Text] [Related]
25. A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.
Silvani A; Franceschi E
Tumori; 2024 Jun; 110(3):160-161. PubMed ID: 38166539
[No Abstract] [Full Text] [Related]
26. Genetic profiling of rat gliomas and cardiac schwannomas from life-time radiofrequency radiation exposure study using a targeted next-generation sequencing gene panel.
Brooks AM; Vornoli A; Kovi RC; Ton TVT; Xu M; Mashal A; Tibaldi E; Gnudi F; Li JL; Sills RC; Bucher JR; Mandrioli D; Belpoggi F; Pandiri AR
PLoS One; 2024; 19(1):e0296699. PubMed ID: 38232086
[TBL] [Abstract][Full Text] [Related]
27. Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials.
Sharma N; Mallela AN; Shi DD; Tang LW; Abou-Al-Shaar H; Gersey ZC; Zhang X; McBrayer SK; Abdullah KG
Neurooncol Adv; 2023; 5(1):vdad053. PubMed ID: 37287696
[TBL] [Abstract][Full Text] [Related]
28. Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas.
Bredel M; Espinosa L; Kim H; Scholtens DM; McElroy JP; Rajbhandari R; Meng W; Kollmeyer TM; Malta TM; Quezada MA; Harsh GR; Lobo-Jarne T; Solé L; Merati A; Nagaraja S; Nair S; White JJ; Thudi NK; Fleming JL; Webb A; Natsume A; Ogawa S; Weber RG; Bertran J; Haque SJ; Hentschel B; Miller CR; Furnari FB; Chan TA; Grosu AL; Weller M; Barnholtz-Sloan JS; Monje M; Noushmehr H; Jenkins RB; Rogers CL; MacDonald DR; Pugh SL; Chakravarti A
Cell Rep Med; 2023 Jun; 4(6):101082. PubMed ID: 37343523
[TBL] [Abstract][Full Text] [Related]
29. AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
Bunse L; Rupp AK; Poschke I; Bunse T; Lindner K; Wick A; Blobner J; Misch M; Tabatabai G; Glas M; Schnell O; Gempt J; Denk M; Reifenberger G; Bendszus M; Wuchter P; Steinbach JP; Wick W; Platten M
Neurol Res Pract; 2022 May; 4(1):20. PubMed ID: 35599302
[TBL] [Abstract][Full Text] [Related]
30. New insights into the Immune TME of adult-type diffuse gliomas.
Richard Q; Laurenge A; Mallat M; Sanson M; Castro-Vega LJ
Curr Opin Neurol; 2022 Dec; 35(6):794-802. PubMed ID: 36226710
[TBL] [Abstract][Full Text] [Related]
31. Cerebellar high-grade astrocytoma with IDH mutations in the elderly: A report of two cases.
Matsumura N; Ikota H; Yamazaki T; Nakata S; Nobusawa S; Hirato J; Yoshimoto Y; Yokoo H
Neuropathology; 2018 Apr; ():. PubMed ID: 29635724
[TBL] [Abstract][Full Text] [Related]
32. Emerging targets for anticancer vaccination: IDH.
Platten M; Bunse L; Wick W
ESMO Open; 2021 Aug; 6(4):100214. PubMed ID: 34271312
[TBL] [Abstract][Full Text] [Related]
33. Radiosensitization of IDH-Mutated Gliomas through ZMYND8 - a Pathway to Improved Outcomes.
Sachdev S; Dmello C; Sonabend AM
Clin Cancer Res; 2023 May; 29(9):1648-1650. PubMed ID: 36826993
[TBL] [Abstract][Full Text] [Related]
34. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma.
Spitzer A; Gritsch S; Nomura M; Jucht A; Fortin J; Raviram R; Weisman HR; Gonzalez Castro LN; Druck N; Chanoch-Myers R; Lee JJY; Mylvaganam R; Lee Servis R; Fung JM; Lee CK; Nagashima H; Miller JJ; Arrillaga-Romany I; Louis DN; Wakimoto H; Pisano W; Wen PY; Mak TW; Sanson M; Touat M; Landau DA; Ligon KL; Cahill DP; Suvà ML; Tirosh I
Cancer Cell; 2024 May; 42(5):904-914.e9. PubMed ID: 38579724
[TBL] [Abstract][Full Text] [Related]
35. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X
Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182
[TBL] [Abstract][Full Text] [Related]
36. IDH-mutant brainstem glioma.
Ryzhova MV; Galstyan SA; Telysheva EN; Pitskhelauri DI; Kosyrkova AV; Latyshev YA
Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(6):52-57. PubMed ID: 36534624
[TBL] [Abstract][Full Text] [Related]
37. Oncological, cognitive, and employment outcomes in a series of patients with IDH-mutated glioma resected following neoadjuvant chemotherapy.
Bursi M; Rizzo C; Barberis M; Poisson I; Lehman-Che J; Adle-Biassette H; Froelich S; Mandonnet E
Acta Neurochir (Wien); 2023 Sep; 165(9):2461-2471. PubMed ID: 37482554
[TBL] [Abstract][Full Text] [Related]
38. Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.
Picca A; Finocchiaro G
Curr Opin Oncol; 2022 Nov; 34(6):653-660. PubMed ID: 36000367
[TBL] [Abstract][Full Text] [Related]
39. IDH inhibition in gliomas: from preclinical models to clinical trials.
Rudà R; Horbinski C; van den Bent M; Preusser M; Soffietti R
Nat Rev Neurol; 2024 May; ():. PubMed ID: 38760442
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of integrative genomic approaches for IDH-mutant gliomas.
Gallo M
Neuro Oncol; 2023 Nov; 25(11):2042-2043. PubMed ID: 37591307
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
